# NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

> **NCT06299163** · PHASE1 · TERMINATED · sponsor: **Numab Therapeutics AG** · enrollment: 11 (actual)

## Conditions studied

- Ovarian Carcinoma
- Fallopian Tube Carcinoma
- Peritoneal Carcinoma
- Endometrial Cancer
- Adenocarcinoma of Lung
- Triple Negative Breast Cancer
- Liposarcoma
- Leiomyosarcoma
- Mesothelioma, Malignant
- Adenocarcinoma - Gastroesophageal Junction (GEJ)
- Adenocarcinoma of the Stomach
- Melanoma, Malignant
- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** NM32-2668

## Key facts

- **NCT ID:** NCT06299163
- **Lead sponsor:** Numab Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-05-01
- **Primary completion:** 2025-04-18
- **Final completion:** 2025-04-18
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06299163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06299163, "NM32-2668 in Adult Patients With Selected Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06299163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*